MedPage Today | Case of PML Linked to Jakafi MedPage Today More recently, PML has struck patients treated with drugs targeting specific elements of the immune system, such as natalizumab (Tysabri), rituximab (Rituxan), and dimethyl fumarate (Fumaderm). Ruxolitinib is an inhibitor of the JAK-1 and JAK-2 kinase ... |
